Oppenheimer stays Outperform on BioAge Labs Inc (BIOA) following Q4 earnings update

March 24, 2026 3:04 PM

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $60.00 price target on BioAge Labs Inc (NASDAQ: BIOA)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found